What is the Future of Open Intraperitoneal Power-Morcellation of Fibroids?

@article{Parker2016WhatIT,
  title={What is the Future of Open Intraperitoneal Power-Morcellation of Fibroids?},
  author={William H Parker and Elizabeth Anna Pritts and David L. Olive},
  journal={Clinical obstetrics and gynecology},
  year={2016},
  volume={59 1},
  pages={73-84}
}
In November 2014, the Food and Drug Administration (FDA) calculated that for every 498 women having surgery for presumed fibroids, one woman would be found to have an occult leiomyosarcoma (LMS). The FDA issued a safety communication warning against the use of laparoscopic morcellators in the majority of women undergoing myomectomy or hysterectomy for treatment of fibroids. This communication was prompted by concern that if a patient had an occult LMS, the morcellator might spread tumor cells… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…